AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Determine which index fund delivers stronger rolling returns using straightforward comparisons and key performance signals.
28,161 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Two senior DeepMind researchers left within 48 hours, jolting Alphabet's AI strategy and sending shockwaves through t...
Idaho's dairy industry, valued at about $20 billion, is grappling with labor shortages driven by tightened immigratio...
Dave Portnoy walked away from an $80,000 salary to launch Barstool Sports, hand-delivering papers in a used van while...
The housing story of 2026 isn’t about a vanished dream. It’s about where the American Dream still thrives—where build...
A growing wave of retirees is eyeing Ecuador to live on about $2,000 a month. This report breaks down costs, visa rul...
With a midnight deadline looming, Trump says won’t sign the bipartisan housing package, risking automatic enactment. ...
A new forecast from the most powerful claude model signals a substantial Solana rally by year-end 2026, backed by ris...
A UK-listed bitcoin treasury company uncovers a counterintuitive edge: buying back its own stock can yield about 24% ...
A man breached the Mar-a-Lago perimeter and was killed in a confrontation with Secret Service and a local deputy. The...
Nvidia delivered a record quarterly revenue of $68.1 billion and projected $78 billion for the coming quarter, driven...
Lighter’s upgraded liquidity framework held firm during a $50 million ARC perpetual squeeze, enforcing a $75,000 cap ...